In this webinar, hosted by DDW, learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its 'Every Compound a Candidate (ECC)" approach, Evotec is aiming to reduce timelines to under two years.

This webinar will explore the current challenges facing small molecule drug discovery and how Evotec's approach, which combines operational excellence with calculated risk-taking in decision-making, can accelerate drug discovery while improving quality.

You will hear from: 

• Ashley Jarvis, EVP, Head of Global Chemistry
• Dermot McGinnity, EVP, Head of Global Discovery DMPK
• Christophe Boldron, VP, Head of Molecular Architects Toulouse
• Jerome Meneyrol, VP Discovery Chemistry, Molecular Architects